Previous 10 | Next 10 |
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced it appointed Shlomi Nachman to its Board of Directors. Mr. Nachman’s long and d...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming 42 nd Annual J.P. Morgan Healthc...
2023-11-29 08:53:57 ET More on AtriCure AtriCure: Appeal Lures For This Cure AtriCure, Inc. (ATRC) Q3 2023 Earnings Call Transcript Needham says Medtronic could create overhang on AtriCure shares Seeking Alpha’s Quant Rating on AtriCure Histori...
2023-11-28 15:12:37 ET More on AtriCure, Medtronic, etc. 3.5% Yield And Over 15% Annual Return Potential - I Really Like Medtronic Medtronic plc (MDT) Q4 2024 Earnings Call Transcript Medtronic: 3 Key Issues To Consider Ahead Of Fiscal Q2 2024 Earnings Bigges...
2023-11-26 22:07:39 ET Summary The article discusses the factors that have led to the undervaluation of the MedTech sector, including the rise in interest rates, opposition to corporate acquisitions by the FTC, and the impact of GLP-1-based treatments. I defend the importance of M...
2023-11-22 23:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Piper Sandler 35 th Annual Healt...
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced that the company has published its 2023 Environmental, Social and Governance (ESG) Rep...
2023-11-10 14:59:56 ET Summary AtriCure has seen solid revenue growth but needs more operating leverage to improve its bottom line. The company's shares have experienced a meaningful pullback from their highs in June. Despite continued losses, AtriCure's progress on the margin...
2023-11-01 22:58:04 ET AtriCure, Inc. (ATRC) Q3 2023 Earnings Conference Call November 1, 2023 4:30 PM ET Company Participants Marissa Bych – Gilmartin Group, Investor Relations Mike Carrel – President and Chief Executive Officer Angie Wirick ȁ...
News, Short Squeeze, Breakout and More Instantly...
CFSB Bancorp Inc. (CFSB) is expected to report for Q4 2024 Big 5 Sporting Goods Corporation (BGFV) is expected to report $-0.48 for Q2 2024 Canadian Pacific Kansas City Limited (CP) is expected to report $0.74 for Q2 2024 Captivision Inc. (CAPT) is expected to report for quarter end 2...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Canaccord Genuity 44th...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it has received regulatory approval from the National Medical Products A...